Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0822A · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| MK0822A | DRUG | - |
Inclusion Criteria: * Man or a woman 70 years old or older in general good health Exclusion Criteria: * Having any form of neurological impairments that may impair motor function.
MK0822A is an investigational small molecule being studied for the treatment of vitamin D deficiency in elderly subjects. It is being developed by Merck & Company, Inc. (MRK). The drug is currently in Phase 2 clinical development.
MK0822A is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's effectiveness in treating vitamin D deficiency.
MK0822A is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to assess its safety and effectiveness.
MK0822A has one completed Phase 2 clinical trial, identified as NCT00242476. This study, titled "A Study to Assess the Effectiveness of an Investigational Drug in Elderly Subjects With Low Vitamin D Levels (0822A-009)," enrolled 216 participants aged 70 years and older.
MK0822A is also referred to as 0822A in clinical trial documentation. The trial NCT00242476 is titled "A Study to Assess the Effectiveness of an Investigational Drug in Elderly Subjects With Low Vitamin D Levels (0822A-009)," indicating the drug's alternative name.